Femtogenix Ltd., of Harpenden, U.K., which is developing the next generation of DNA-interactive antibody drug conjugate (ADC) payloads, said data verifying the favorable toxicity profile and potent efficacy of its pyridinobenzodiazepine (PDD) ADC payload platform in tumor cell models were presented at the World ADC 2019 meeting in San Diego.